[go: up one dir, main page]

MX354843B - Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia. - Google Patents

Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia.

Info

Publication number
MX354843B
MX354843B MX2012005031A MX2012005031A MX354843B MX 354843 B MX354843 B MX 354843B MX 2012005031 A MX2012005031 A MX 2012005031A MX 2012005031 A MX2012005031 A MX 2012005031A MX 354843 B MX354843 B MX 354843B
Authority
MX
Mexico
Prior art keywords
vaccine
pneumoniae capsular
streptococcus pneumoniae
conjugates
vaccines
Prior art date
Application number
MX2012005031A
Other languages
English (en)
Inventor
Paulette Van Mechelen Marcelle
Poolman Jan
Leon Biemans Ralph
Marie-Josephe Garcon Nathalie
Vincent Hermand Philippe
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39133667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354843(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526232A external-priority patent/GB0526232D0/en
Priority claimed from GBGB0607088.2A external-priority patent/GB0607088D0/en
Priority claimed from GB0607087A external-priority patent/GB0607087D0/en
Priority claimed from GB0609902A external-priority patent/GB0609902D0/en
Priority claimed from GBGB0620336.8A external-priority patent/GB0620336D0/en
Priority claimed from GB0620337A external-priority patent/GB0620337D0/en
Priority claimed from GB0620816A external-priority patent/GB0620816D0/en
Priority claimed from GB0620815A external-priority patent/GB0620815D0/en
Priority claimed from PCT/GB2006/004634 external-priority patent/WO2007068907A2/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX354843B publication Critical patent/MX354843B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición inmunogénica que comprende conjugados de sacáridos capsulares de S. pneumoniae de los serotipos 19A y 19F en donde 19A está conjugado a un primer toxoide bacteriano y 19F está conjugado a un segundo toxoide bacteriano. También se describen las vacunas, métodos de fabricación de vacunas y aplicaciones de las vacunas.
MX2012005031A 2005-12-22 2006-12-20 Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia. MX354843B (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB0526232A GB0526232D0 (en) 2005-12-22 2005-12-22 Vaccine
GBGB0607088.2A GB0607088D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0607087A GB0607087D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0609902A GB0609902D0 (en) 2006-05-18 2006-05-18 Novel composition
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620816A GB0620816D0 (en) 2006-10-19 2006-10-19 vaccine
GB0620815A GB0620815D0 (en) 2006-10-19 2006-10-19 Vaccine
PCT/GB2006/004634 WO2007068907A2 (en) 2005-12-13 2006-12-12 Vaccine compositions comprising a saponin adjuvant
PCT/EP2006/069977 WO2007071710A2 (en) 2005-12-22 2006-12-20 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates

Publications (1)

Publication Number Publication Date
MX354843B true MX354843B (es) 2018-03-22

Family

ID=39133667

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008008140A MX2008008140A (es) 2005-12-22 2006-12-20 Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia.
MX2012005031A MX354843B (es) 2005-12-22 2006-12-20 Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2008008140A MX2008008140A (es) 2005-12-22 2006-12-20 Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia.

Country Status (37)

Country Link
US (10) US20090017059A1 (es)
EP (10) EP3470080A1 (es)
JP (7) JP5792920B2 (es)
KR (5) KR101365001B1 (es)
CN (6) CN101378778B (es)
AR (3) AR058592A1 (es)
AT (1) ATE520415T1 (es)
AU (4) AU2006327036B2 (es)
BR (3) BRPI0620163B8 (es)
CA (5) CA2633772C (es)
CL (1) CL2013002106A1 (es)
CR (2) CR10119A (es)
CY (5) CY1112677T1 (es)
DK (5) DK1962899T3 (es)
EA (3) EA014107B1 (es)
ES (4) ES2539795T3 (es)
HK (1) HK1120230A1 (es)
HR (4) HRP20110685T1 (es)
HU (3) HUE033081T2 (es)
IL (5) IL191911A (es)
JO (1) JO2813B1 (es)
LT (3) LT3017827T (es)
MA (3) MA30066B1 (es)
MX (2) MX2008008140A (es)
MY (4) MY148141A (es)
NO (4) NO345368B1 (es)
NZ (4) NZ569076A (es)
PE (2) PE20071305A1 (es)
PH (1) PH12014502544A1 (es)
PL (5) PL2384765T3 (es)
PT (5) PT1962899E (es)
SG (1) SG168517A1 (es)
SI (5) SI3017827T1 (es)
TR (1) TR201900418T4 (es)
TW (4) TW201350129A (es)
UA (2) UA96583C2 (es)
WO (3) WO2007071711A2 (es)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1946769E (pt) * 2000-06-29 2012-06-27 Smithkline Beecham Biolog Composição de vacina multivalente com dose reduzida de haemophilus influenzae de tipo b
AU1486102A (en) * 2000-11-07 2002-05-21 Immunovaccine Technologies Inc Vaccines with enhanced immune response and methods for their preparation
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
PT1896061T (pt) 2005-06-27 2019-08-01 Glaxosmithkline Biologicals Sa Composição imunogénica
TR201900418T4 (tr) 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
WO2008022299A1 (en) * 2006-08-17 2008-02-21 The Uab Research Foundation Diagnosing pneumococcal pneumonia
WO2008129559A2 (en) * 2007-04-23 2008-10-30 Serum Institute Of India Ltd Antigenic polysaccharides and process for their preparation
AU2008248640A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
KR101579947B1 (ko) * 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101827613A (zh) 2007-09-27 2010-09-08 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
AU2009208403A1 (en) 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
ES2678694T3 (es) * 2008-04-16 2018-08-16 Glaxosmithkline Biologicals Sa Vacuna
MX2010011393A (es) * 2008-04-16 2010-11-09 Glaxosmithkline Biolog Sa Vacuna.
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010109324A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
NZ595223A (en) * 2009-03-24 2013-12-20 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
MX340830B (es) 2009-04-30 2016-07-26 Coley Pharm Group Inc Vacuna neumococica y usos de la misma.
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
KR20110068831A (ko) * 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 리포좀 조성물, 그 제조방법, 및 폐렴 백신으로서의 그 용도
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
KR20140026392A (ko) * 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
SG194733A1 (en) * 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
RU2634405C2 (ru) * 2012-01-30 2017-10-26 Серум Инститьют Оф Индия Лтд. Иммуногенная композиция
EP2809785B1 (en) 2012-02-02 2017-11-01 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
WO2013119856A1 (en) * 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US20150132339A1 (en) * 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
RU2510281C2 (ru) * 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
KR101742406B1 (ko) 2012-08-16 2017-05-31 화이자 인코포레이티드 당접합 공정 및 조성물
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
WO2014045621A1 (ja) * 2012-09-19 2014-03-27 国立大学法人大阪大学 肺炎球菌表面タンパク質ａを含む肺炎球菌ワクチン
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2934574A1 (en) 2012-12-18 2015-10-28 GlaxoSmithKline Biologicals SA Conjugates for protecting against diphtheria and/or tetanus
CA2893343C (en) * 2012-12-20 2019-05-14 Pfizer Inc. Glycoconjugation process
RU2544168C1 (ru) * 2014-01-17 2015-03-10 Андрей Дмитриевич Протасов Способ формирования иммунологической памяти к антигенам streptococcus pneumoniae у пациентов с хронической обструктивной болезнью легких
HUE055408T2 (hu) 2014-01-21 2021-12-28 Pfizer Streptococcus pneumoniae kapszuláris poliszacharidok és konjugátumaik
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DK3096785T3 (da) * 2014-01-21 2020-09-21 Pfizer Immunogene sammensætninger omfattende konjugerede kapsel-saccharid-antigener og anvendelser deraf
KR102229568B1 (ko) * 2014-01-21 2021-03-18 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
EP3104886B1 (en) * 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
CN103893751B (zh) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
CN103936842B (zh) * 2014-04-30 2016-03-23 重庆医科大学 肺炎链球菌溶血素突变体及其作为粘膜免疫佐剂的应用
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10280409B2 (en) * 2014-11-20 2019-05-07 Biological E Limited Codon optimized polynucleotide for high level expression of CRM197
EP3273989B1 (en) * 2015-03-26 2023-12-27 Gpn Vaccines Pty Ltd Streptococcal vaccine
IL297740A (en) 2015-05-04 2022-12-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses
RU2600838C1 (ru) * 2015-06-08 2016-10-27 Андрей Дмитриевич Протасов Способ усиления активности факторов неспецифической защиты у пациентов с хронической обструктивной болезнью легких
PE20180460A1 (es) * 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos
KR20160146240A (ko) 2015-06-12 2016-12-21 전관구 염기성 계면활성제를 이용한 산화은나노 및 은나노 제조 방법
LT3313436T (lt) * 2015-06-23 2021-06-10 Biological E Limited Daugiavalentė pneumokokinė konjuguota vakcina
EP3325008A1 (en) * 2015-07-21 2018-05-30 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
EP3493840B1 (en) * 2016-08-05 2022-08-24 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
AU2016425290A1 (en) * 2016-09-27 2019-04-11 Immunovaccine Technologies Inc. Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
MX2019003593A (es) * 2016-09-30 2019-06-10 Biological E Ltd Composiciones de vacuna neumococica multivalente que comprenden conjugados de polisacaridos y proteinas.
WO2018074296A1 (ja) * 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
WO2018080213A1 (ko) * 2016-10-28 2018-05-03 주식회사 엘지화학 향상된 IgG 역가를 갖는 다가면역원성 조성물 및 이의 용도
CN108144052A (zh) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 肺炎链球菌多糖-蛋白质缀合物及其制取方法和用途
EP3562838A2 (en) 2016-12-28 2019-11-06 Henriques Normark, Birgitta Microparticles from streptococcus pneumoniae as vaccine antigens
EP3562503A2 (en) * 2016-12-30 2019-11-06 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
HUE059252T2 (hu) * 2017-01-20 2022-11-28 Pfizer Immunogén készítmények pneumokokkusz vakcinákban történõ alkalmazásra
EP3576759A4 (en) * 2017-01-31 2020-11-11 Merck Sharp & Dohme Corp. PROCESSES FOR THE PRODUCTION OF CAPSULAR PROTEIN-POLYSACCHARIDE CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SERTYPE 19F
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN107929728A (zh) * 2017-04-19 2018-04-20 武汉博沃生物科技有限公司 一种肺炎球菌蛋白疫苗及其制备方法
US10729763B2 (en) * 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR20240018698A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
CN111093649B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
MX2020002556A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
EP3678694A4 (en) * 2017-09-07 2021-10-20 Merck Sharp & Dohme Corp. METHODS FOR FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION WITH A CARRIER PROTEIN
MA51048A (fr) 2017-12-06 2021-03-17 Merck Sharp & Dohme Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
KR20200121822A (ko) 2018-02-05 2020-10-26 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
CA3096358A1 (en) 2018-04-18 2019-10-24 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
JP7506605B6 (ja) * 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
CN108524926B (zh) * 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
JP7399934B2 (ja) * 2018-07-04 2023-12-18 バックスサイト・インコーポレイテッド 免疫原性複合体の改良
EP3849587A4 (en) * 2018-09-12 2022-06-29 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2020075201A1 (en) 2018-10-12 2020-04-16 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
MX2021007496A (es) 2018-12-19 2021-08-05 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso.
AU2020315673B2 (en) * 2019-07-18 2025-01-23 Celltrion, Inc. Immunogenic composition comprising multivalent Streptococcus pneumoniae polysaccharide-protein conjugates
US20210070890A1 (en) 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
MX2022003324A (es) 2019-09-18 2022-04-18 Alcon Inc Insertos oculares de hidrogel blando envasados en humedo.
US20210220461A1 (en) * 2020-01-17 2021-07-22 Inventprise, Llc Multivalent Streptococcus Vaccines
KR20210117663A (ko) 2020-03-20 2021-09-29 주식회사 보고 수직형 침지식 dpf 세척장치
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
CN113293115B (zh) * 2021-07-08 2022-08-26 成都生物制品研究所有限责任公司 肺炎链球菌无动物源冻干保护剂
KR20240055283A (ko) 2022-10-20 2024-04-29 우남철 Ｄｐｆ용 순환펌프 연결구
WO2024180472A1 (en) 2023-02-28 2024-09-06 Alcon Inc. Ocular inserts

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
AU626961B2 (en) 1988-12-16 1992-08-13 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
DE69226167T2 (de) 1991-02-15 1998-11-12 The Uab Research Foundation, Birmingham, Alabama Strukturgen von pneumokokken-protein
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
KR950700081A (ko) 1992-02-11 1995-01-16 W 로우 죤 이중 캐리어 면역원성 구성물
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
AU671649B2 (en) 1992-06-18 1996-09-05 President And Fellows Of Harvard College Diphtheria toxin vaccines
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
EP0699076B1 (en) 1993-05-18 2002-10-30 The Ohio State University Research Foundation Otitis media vaccine
AU678613B2 (en) 1993-09-22 1997-06-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
ES2262177T3 (es) 1996-05-01 2006-11-16 The Rockefeller University Proteinas de union a colina para vacunas frente a neumococos.
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
DK0914178T3 (da) 1996-06-18 2003-04-22 Alza Corp Anordning til forøgelse af transdermal afgivelse eller prøveudtagning af et middel
WO1998006734A1 (en) 1996-08-16 1998-02-19 Smithkline Beecham Corporation Novel prokaryotic polynucleotides, polypeptides and their uses
DK0942983T4 (en) 1996-10-31 2014-12-01 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
EP0942984A2 (en) 1996-11-12 1999-09-22 Regents Of The University Of Minnesota C3 BINDING PROTEIN OF $i(STREPTOCOCCUS PNEUMONIAE)
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CN1133472C (zh) 1996-12-20 2004-01-07 阿尔萨公司 增加经皮样剂流量的装置
DE19708537A1 (de) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
NZ501911A (en) 1997-06-03 2001-12-21 Connaught Lab Lactoferrin receptor genes (Lbp1, Lbp2 and/or ORF3) of Moraxella to be used in diagnosis or treatment of Moraxella related diseases such conjunctivitis, sinusitis or urogenital infections
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
AU9510598A (en) 1997-09-24 1999-04-12 American Cyanamid Company Human complement c3-degrading proteinase from (streptococcus pneumoniae)
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
IL136488A0 (en) 1997-12-02 2001-06-14 Powderject Vaccines Inc Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
NZ530277A (en) 1998-04-07 2005-08-26 Medimmune Inc Derivatives of pneumococcal choline binding proteins for vaccines
KR100638503B1 (ko) 1998-04-07 2006-10-26 세인트 쥬드 칠드런즈 리써치 호스피탈 Ｎ-말단 콜린 결합 단백질 ａ 절두물의 아미노산을 포함하는 폴리펩티드, 이로부터 유도된 백신 및 이를 포함하는 약제학적 조성물
WO1999053940A1 (en) 1998-04-23 1999-10-28 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
KR100704826B1 (ko) 1998-08-19 2007-04-09 박스터 헬쓰케어 에스.에이. Ｎ-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
KR20010089280A (ko) 1998-09-24 2001-09-29 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 인간 보체 ｃ3 분해폴리펩티드
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB2359228A (en) 1998-11-17 2001-08-15 Schlumberger Technology Corp Transmitting information over a communication link
WO2000029434A2 (en) 1998-11-19 2000-05-25 St. Jude Children's Research Hospital PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
JP4689044B2 (ja) * 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
TR200200633T2 (tr) 1998-12-23 2002-06-21 Shire Biochem Inc. Yeni streptococcus antijenleri
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
CZ303653B6 (cs) * 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
JP2002542203A (ja) 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
EP1185297B1 (en) 1999-06-10 2006-05-10 MedImmune, Inc. Streptococcus pneumoniae proteins and vaccines
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20040191834A1 (en) * 1999-10-28 2004-09-30 Laferriere Craig Antony Joseph Novel method
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001098334A2 (en) 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1946769E (pt) * 2000-06-29 2012-06-27 Smithkline Beecham Biolog Composição de vacina multivalente com dose reduzida de haemophilus influenzae de tipo b
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ES2261453T3 (es) 2000-08-04 2006-11-16 Corixa Corporation Nuevos compuestos inmunoefectores.
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
FR2827199B1 (fr) 2001-07-10 2004-07-09 Centre Nat Rech Scient Procede et machine de fabrication ex situ de reseaux de biopuces basse et moyennes integration
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP1456231A2 (en) 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
ATE447844T1 (de) 2002-02-04 2009-11-15 Corixa Corp Neue immuneffektor-verbindungen
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
PL220107B1 (pl) 2002-08-02 2015-08-31 Glaxosmithkline Biolog Sa Preparat immunogenny, szczepionka oraz zastosowanie tej szczepionki
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
JP3754420B2 (ja) 2003-02-04 2006-03-15 三洋電機株式会社 二次電池用電極板及びその製造方法並びにこの電極板を用いた二次電池
WO2004081515A2 (en) 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP1638602A1 (en) 2003-06-23 2006-03-29 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
KR101270838B1 (ko) 2004-05-11 2013-07-04 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 폭스겐트존하이트 벨지인 엔 스포츠 보조제로서의 나이세리아 메닌자이티디스 ＩｇｔＢ ＬＯＳ
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
PT1896061T (pt) 2005-06-27 2019-08-01 Glaxosmithkline Biologicals Sa Composição imunogénica
CN102973929B (zh) 2005-09-01 2017-04-26 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
EP1945249A2 (en) 2005-11-01 2008-07-23 Novartis AG Compositions with antigens adsorbed to calcium phosphate
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
TR201900418T4 (tr) * 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
CA2650590C (en) 2006-04-26 2018-04-03 Micell Technologies, Inc. Coatings containing multiple drugs
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
JP5789514B2 (ja) 2008-12-18 2015-10-07 ワイス・エルエルシー 二酸化炭素を用いて肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）多糖の分子量を制御するための方法

Also Published As

Publication number Publication date
BRPI0620193A2 (pt) 2011-11-01
WO2007071710A3 (en) 2007-11-29
EP3470080A1 (en) 2019-04-17
WO2007071707A2 (en) 2007-06-28
US20160243219A1 (en) 2016-08-25
IL219641A (en) 2017-10-31
UA96934C2 (uk) 2011-12-26
NZ569077A (en) 2011-08-26
EP2382986A2 (en) 2011-11-02
TWI487534B (zh) 2015-06-11
EP1973564A2 (en) 2008-10-01
NO20082647L (no) 2008-09-18
JP5792920B2 (ja) 2015-10-14
CN101374548B (zh) 2013-05-01
DK1973564T3 (da) 2017-01-16
DK3017827T3 (en) 2019-02-18
SG168517A1 (en) 2011-02-28
PT2384765T (pt) 2017-02-06
US20190262447A1 (en) 2019-08-29
EP1962899B1 (en) 2011-08-17
JP2009520761A (ja) 2009-05-28
EP2384765A3 (en) 2012-06-20
NO343981B1 (no) 2019-08-05
KR20130103831A (ko) 2013-09-24
CA2808919C (en) 2016-04-19
KR101367237B1 (ko) 2014-03-14
PL1973564T3 (pl) 2017-04-28
EP1968631B1 (en) 2015-04-08
CN110179974A (zh) 2019-08-30
CN101374548A (zh) 2009-02-25
CN101378778A (zh) 2009-03-04
CA2634885A1 (en) 2007-06-28
JP5849125B2 (ja) 2016-01-27
PL3017827T3 (pl) 2019-04-30
JP2009520759A (ja) 2009-05-28
KR101365001B1 (ko) 2014-02-21
CY1112677T1 (el) 2016-02-10
CY1118345T1 (el) 2017-06-28
NZ569076A (en) 2011-08-26
CY1121376T1 (el) 2020-05-29
US20180250389A9 (en) 2018-09-06
CN101378779A (zh) 2009-03-04
CR10119A (es) 2008-07-29
KR20080081060A (ko) 2008-09-05
KR101441368B1 (ko) 2014-09-24
HRP20110685T1 (hr) 2011-10-31
PT1962899E (pt) 2011-10-19
PE20071058A1 (es) 2007-11-27
US20220354941A1 (en) 2022-11-10
TW201350129A (zh) 2013-12-16
JP5615323B2 (ja) 2014-10-29
EP3017827A1 (en) 2016-05-11
BRPI0620163B8 (pt) 2021-05-25
UA96583C2 (uk) 2011-11-25
PH12014502544A1 (en) 2015-12-14
CN101378779B (zh) 2015-09-02
TW200738257A (en) 2007-10-16
ES2630759T3 (es) 2017-08-23
IL191913A0 (en) 2009-02-11
JP5600337B2 (ja) 2014-10-01
AR058592A1 (es) 2008-02-13
NO344187B1 (no) 2019-09-30
PL1968631T3 (pl) 2015-08-31
MA30065B1 (fr) 2008-12-01
KR20080081063A (ko) 2008-09-05
US9884113B2 (en) 2018-02-06
KR20140036327A (ko) 2014-03-25
IL191911A (en) 2015-09-24
HRP20161682T1 (hr) 2017-01-27
IL191911A0 (en) 2008-12-29
PT3017827T (pt) 2019-01-28
DK2384765T3 (en) 2017-01-09
US20100074922A1 (en) 2010-03-25
CY1116407T1 (el) 2017-02-08
NZ596500A (en) 2013-05-31
AU2006327041B2 (en) 2010-08-26
JP2014205673A (ja) 2014-10-30
US20180207262A1 (en) 2018-07-26
US20090010959A1 (en) 2009-01-08
SI1968631T1 (sl) 2015-07-31
CN103251940A (zh) 2013-08-21
CL2013002106A1 (es) 2014-03-07
EP3020411A1 (en) 2016-05-18
AU2006327040B2 (en) 2010-08-19
KR101515078B1 (ko) 2015-04-24
ATE520415T1 (de) 2011-09-15
EA200801374A1 (ru) 2008-12-30
US20090017072A1 (en) 2009-01-15
AU2006327041A1 (en) 2007-06-28
MA30066B1 (fr) 2008-12-01
SI3017827T1 (sl) 2019-01-31
TWI465248B (zh) 2014-12-21
NO20190104A1 (no) 2008-09-18
NO345368B1 (no) 2021-01-04
MA30062B1 (fr) 2008-12-01
NO20082646L (no) 2008-09-16
SI1973564T1 (sl) 2017-02-28
CR10122A (es) 2008-08-21
NO20082718L (no) 2008-09-16
AR058706A1 (es) 2008-02-20
EP2402025A2 (en) 2012-01-04
US20150190521A1 (en) 2015-07-09
EA014107B1 (ru) 2010-10-29
CY1118535T1 (el) 2017-07-12
SI2384765T1 (sl) 2017-03-31
MY150719A (en) 2014-02-28
BRPI0620460B8 (pt) 2021-05-25
EA200801344A1 (ru) 2008-12-30
NO346529B1 (no) 2022-09-26
HUE041979T2 (hu) 2019-06-28
KR101418240B1 (ko) 2014-07-16
CN103585623A (zh) 2014-02-19
CA2634887C (en) 2016-01-19
WO2007071711A3 (en) 2007-11-08
TR201900418T4 (tr) 2019-02-21
KR20080081061A (ko) 2008-09-05
US20150265702A1 (en) 2015-09-24
HK1120230A1 (en) 2009-03-27
MY148141A (en) 2013-03-15
CA2634885C (en) 2016-04-19
TW200738258A (en) 2007-10-16
JP2012211165A (ja) 2012-11-01
CN103585623B (zh) 2016-09-28
JP5461838B2 (ja) 2014-04-02
WO2007071707A3 (en) 2007-09-13
AU2010241281B2 (en) 2012-12-06
SI1962899T1 (sl) 2011-11-30
CA2634887A1 (en) 2007-06-28
CN110179974B (zh) 2024-01-09
IL219641A0 (en) 2012-06-28
IL211664A0 (en) 2011-05-31
BRPI0620460B1 (pt) 2019-08-13
NZ569168A (en) 2012-02-24
CA2633772C (en) 2015-09-15
PL2384765T3 (pl) 2017-05-31
BRPI0620193B8 (pt) 2021-05-25
US10279033B2 (en) 2019-05-07
EP2384765A2 (en) 2011-11-09
MY160199A (en) 2017-02-28
MX2008008140A (es) 2008-09-24
JP2009520760A (ja) 2009-05-28
JP5749689B2 (ja) 2015-07-15
BRPI0620193B1 (pt) 2019-12-31
CA2633772A1 (en) 2007-06-28
ES2614938T3 (es) 2017-06-02
AU2006327036B2 (en) 2012-11-15
EA014165B1 (ru) 2010-10-29
CA2816182C (en) 2018-02-20
AU2006327036A1 (en) 2007-06-28
HUE032903T2 (hu) 2017-11-28
EP2384765B1 (en) 2016-11-23
TWI415622B (zh) 2013-11-21
HRP20190037T1 (hr) 2019-02-22
WO2007071711A2 (en) 2007-06-28
EP1968631A2 (en) 2008-09-17
JP2012232985A (ja) 2012-11-29
EP1973564B1 (en) 2016-11-09
EP3130348A1 (en) 2017-02-15
DK1968631T3 (da) 2015-06-15
LT3017827T (lt) 2019-01-10
AU2006327040A1 (en) 2007-06-28
HRP20161681T1 (hr) 2017-01-13
IL191913A (en) 2012-07-31
BRPI0620163A2 (pt) 2011-11-01
JO2813B1 (en) 2014-09-15
DK1962899T3 (da) 2011-10-31
EP1962899A2 (en) 2008-09-03
US10646564B2 (en) 2020-05-12
PL1962899T3 (pl) 2011-12-30
BRPI0620460A2 (pt) 2011-11-16
IL192084A0 (en) 2008-12-29
EP3017827B1 (en) 2018-11-07
CA2816182A1 (en) 2007-06-28
AU2010241281A1 (en) 2010-11-25
JP5579387B2 (ja) 2014-08-27
US9107872B2 (en) 2015-08-18
LT1973564T (lt) 2016-12-27
PE20071305A1 (es) 2007-12-14
LT2384765T (lt) 2017-01-10
WO2007071710A2 (en) 2007-06-28
PT1973564T (pt) 2017-01-24
IL192084A (en) 2013-11-28
ES2539795T3 (es) 2015-07-06
CA2808919A1 (en) 2007-06-28
HUE033081T2 (hu) 2017-11-28
BRPI0620163B1 (pt) 2019-08-13
WO2007071710A8 (en) 2008-09-04
EP2402025A3 (en) 2012-03-07
AR058707A1 (es) 2008-02-20
EP2382986A3 (en) 2012-08-22
US20090017059A1 (en) 2009-01-15
ES2707499T3 (es) 2019-04-03
EA014649B1 (ru) 2010-12-30
PT1968631E (pt) 2015-07-20
CN101378778B (zh) 2013-02-06
EA200801367A1 (ru) 2008-12-30
MY147495A (en) 2012-12-14
JP2012229228A (ja) 2012-11-22
US11400147B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
MX354843B (es) Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia.
WO2009000824A3 (en) Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
MY145150A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
MX336934B (es) Composicion conjugada polisacarido-proteina neumococica multivalente.
WO2002091998A3 (en) Novel meningitis conjugate vaccine
NZ595178A (en) Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
MY159984A (en) 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
UA99703C2 (en) Use of streptococcus pneumoniae immunogenic composition